when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

PI3K · news · pharmadog

← back to PI3K

News · PI3K

27 stories

4dHalozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialbiopharma dive

5dKymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offeringsendpoints

Sep 10, 26In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacyfiercebiotech

Aug 25, 26After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformfiercebiotech

Jul 15, 26Celcuity gains FDA approval for closely watched breast cancer drugbiopharma dive

Jun 2, 26Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialbiopharma dive

May 19, 26Relay drug shows early promise against rare blood vessel diseasesbiopharma dive

May 19, 26Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies studyendpoints

May 12, 26Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bondonclive

May 11, 26Dr Silbermann on Clinical Trial Design Considerations in Multiple Myelomaonclive

May 11, 26MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumorsonclive

May 11, 26Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTonclive

May 11, 26Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selectiononclive

May 11, 26Expanding ctDNA Applications to RCC and Germ Cell Tumorsonclive

May 11, 26RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practiceonclive

May 11, 26ctDNA in Metastatic Urothelial Carcinomaonclive

May 11, 26Institutional Perspectives on Treatment Thresholds in PLGGonclive

May 11, 26Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groupsonclive

May 10, 26Five Under 5: Top Oncology Videos for the Week of 5/3onclive

May 9, 26The OncFive: Top Oncology Articles for the Week of 5/3onclive

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 8, 26OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updatesonclive

May 6, 26ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Goonclive

May 4, 26Celcuity strengthens case for ASCO-spotlighted breast cancer drugbiopharma dive

May 4, 26Celcuity's breast cancer win; Odyssey plans $205M IPOendpoints

Dec 22, 25Fierce Biotech Fundraising Tracker '26: Matchpoint makes $150M; KymaThera corrals $80Mfiercebiotech